|
YES1 expression based on
|
| Comparison | Statistical significance |
| Normal-vs-Primary | 3.68590002963742E-09 |
|
Note
Cancer stage information is not available for 2 samples.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Stage1 |
1.16429999974521E-07 |
| Normal-vs-Stage2 |
7.407300E-04 |
| Normal-vs-Stage3 |
1.97589999917369E-08 |
| Normal-vs-Stage4 |
4.91759999388108E-09 |
| Stage1-vs-Stage2 |
4.125000E-01 |
| Stage1-vs-Stage3 |
2.291600E-01 |
| Stage1-vs-Stage4 |
3.655600E-02 |
| Stage2-vs-Stage3 |
1.129380E-01 |
| Stage2-vs-Stage4 |
2.676500E-02 |
| Stage3-vs-Stage4 |
4.178800E-01 |
|
|
Note
Patient race information is not available for 92 samples and one samples from American Indians not included in the above plot.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Caucasian |
1.40000000481422E-09 |
| Normal-vs-AfricanAmerican |
3.249800E-02 |
| Normal-vs-Asian |
7.32529999991627E-07 |
| Caucasian-vs-AfricanAmerican |
6.957800E-02 |
| Caucasian-vs-Asian |
8.527400E-01 |
| AfricanAmerican-vs-Asian |
6.911600E-02 |
|
|
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Male |
3.75890000015033E-07 |
| Normal-vs-Female |
6.06929995150551E-09 |
| Male-vs-Female |
9.305800E-01 |
|
|
Note
Seventeen samples from patient below 21 years not considered in above plot.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Age(21-40Yrs) |
7.83950000027289E-07 |
| Normal-vs-Age(41-60Yrs) |
4.55430004819846E-09 |
| Normal-vs-Age(61-80Yrs) |
2.40919999949796E-07 |
| Normal-vs-Age(81-100Yrs) |
9.955900E-03 |
| Age(21-40Yrs)-vs-Age(41-60Yrs) |
2.567800E-01 |
| Age(21-40Yrs)-vs-Age(61-80Yrs) |
7.276200E-01 |
| Age(21-40Yrs)-vs-Age(81-100Yrs) |
6.754800E-01 |
| Age(41-60Yrs)-vs-Age(61-80Yrs) |
5.162600E-01 |
| Age(41-60Yrs)-vs-Age(81-100Yrs) |
9.455200E-01 |
| Age(61-80Yrs)-vs-Age(81-100Yrs) |
7.497200E-01 |
|
|
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Classical-VS-Tall |
3.053000E-01 |
| Classical-VS-Follicular |
3.581200E-01 |
| Classical-VS-Other |
2.569200E-01 |
| Classical-VS-Normal |
2.69490000315287E-08 |
| Tall-VS-Follicular |
1.792180E-01 |
| Tall-VS-Other |
5.172800E-01 |
| Tall-VS-Normal |
1.62182999999816E-05 |
| Follicular-VS-Other |
2.140600E-01 |
| Follicular-VS-Normal |
2.816100E-04 |
| Other-VS-Normal |
1.895380E-03 |
|
|
Note
Cancer in nearby lymph nodes cannot be measured (NX) in 50 samples.
| pathologic_N descriptions |
| N0 | No regional lymph node metastasis |
N1 | Metastases in 1 to 3 axillary lymph nodes |
| N2 | Metastases in 4 to 9 axillary lymph nodes |
N3 | Metastases in 10 or more axillary lymph nodes |
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-N0 |
2.25949999821395E-08 |
| Normal-vs-N1 |
4.4560000023175E-08 |
| N0-vs-N1 |
3.012800E-01 |
|
|
